PatientsVille.com Logo

MYALGIA and Lisinopril

PatientsVille

MYALGIA Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for MYALGIA

MYALGIA treatment research studies

Lisinopril clinical trials, surveys and public health registries


Find Drug Side Effect reports



Lisinopril Side Effects

Angioedema (1910)
Cough (788)
Dyspnoea (519)
Renal Failure Acute (451)
Dizziness (448)
Hyperkalaemia (441)
Swollen Tongue (401)
Hypotension (376)
Fatigue (371)
Nausea (351)
Diarrhoea (317)
Swelling Face (305)
Headache (297)
Lip Swelling (295)
Pain (278)
Blood Pressure Increased (264)
Angioneurotic Oedema (264)
Dysphagia (259)
Asthenia (259)
Completed Suicide (256)
Vomiting (209)
Hypertension (209)
Rash (202)
Pruritus (191)
Fall (163)
Chest Pain (160)
Dehydration (157)
Renal Failure (152)
Syncope (144)
Wheezing (142)
Insomnia (142)
Arthralgia (140)
Malaise (139)
Anxiety (132)
Blood Creatinine Increased (130)
Oedema Peripheral (125)
Toxicity To Various Agents (123)
Feeling Abnormal (119)
Pain In Extremity (117)
Pharyngeal Oedema (117)
Hypersensitivity (113)
Myocardial Infarction (112)
Muscle Spasms (111)
Renal Impairment (110)
Abdominal Pain (109)
Urticaria (109)
Weight Decreased (108)
Back Pain (105)
Paraesthesia (103)
Flushing (103)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I just started taking lisinopril and am also staying very tired. Dizziness and lightheadness are my biggest problems right now.I am taking this with cardura and zoloft, so it may not count here. But i wanted to share my input and after reading the c

56 yo male 6weeks 10mg per day no niticable side effects

56 yo male. 3 weeks, 10mg. per day. no noticable side effects.

After 2yrs of lisinopril got severe rash on legs,knees and buttocks.hands swollen,lips swollen.all this for 6 months before doc and team took me off lisinopril after extensive testing.now on steroids and antibods to clear up.

Al, you may not have the energy right now, but you really need to find the energy to find a good primary care doctor. Cholesterol levels in the 500 are a huge risk. There are other cholesterol meds out there that work gr

Been on 40 mgs aday for 6 yrs now..i never noticed any problems..also on minoxdil...

Been taking lisinopril for about a year. i now have (maybe) not fully diagnosed,polymyalgia rheumatitus. i'm thinking its from the lisinopril. i have muscle pain in my arms whenever i move them to do something,which is often. i also had pain in my up

Can someone please tell how high a CPR reading has to be to determine Polymyalgia Rheumatica.

Chest/or chest tightening

Dizziness

Can arthralgia nad myalgia occur due to cefepime use

I am doctor I tried simovastatin and got myalgia later i tried rozuvastatin and had the same side effect.I had to stop medication because of pain and high color urine

I experienced moderate to severe myalgia shortly after starting Welchol, and it continues to this day. (6 months later.) Only Co Q 10 helps.

I have been taking Rebif since Nov-2005 with generally few problems beyond routine myalgia the day following the injection, some occasional redness at the injection sites, and some fat deposits that seem to be forming under my skin at some of the inj

I used Restasis for a few weeks and developed hypertension, fatigue, as well as myalgia and arthralgia. Doctor did not think it was the Restasis but I discontinued use and within a few weeks, symptoms were gone.

I was given Rifampin for lymes about 18 months ago. Until that time I didn't have myalgia. While the pain is diminishing, it is still life altering. I have never felt such pain in my life (including child birth). It was combined with doxycycline.

Myalgia, pain in all my muscles and very stiff.

Severe myalgia mucsle pain ,weight lose, dysphagia, mildly elevated mucsle enzyme, positive EMG for four limbs , jaw pain and mucsle waisting sick appearance . DM.HTN.HYPERLIPEADEMIC,10 years on: Crestor 20mg, galvous50mgx2, metformin 500

This is interesting. I have taken Ezetrol for a few years. Over that time I have developed acute myalgia over my entire body. It was not localized in the joints, but seemed to be spread throughout my muscle tissue. At times it took great effort just

MYALGIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting Bedtime Administration of Amlodipine Versus Lisinopril
Condition: Hypertension
Intervention: Drug: Amlodipine
Outcome Measures: Change in mean sleep-time systolic blood pressure after addition of a bedtime dose of amlodipine versus Lisinopril;   Changes in mean sleep-time diastolic, awake systolic and diastolic blood pressures, including comparison of % achieving target BP;   Impact of individual medications on sleep-time blood pressure drop (dipping status);   Association of baseline renin levels to sleep-time blood pressure drop;   Association of baseline renin levels with response to amlodipine versus Lisinopril;   Association of baseline dipping status with response to amlodipine versus Lisinopril;   Association of age and response to amlodipine versus Lisinopril
2 Recruiting Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
Conditions: Breast Cancer;   Cardiac Toxicity
Interventions: Drug: Coreg CR®;   Drug: Lisinopril;   Other: placebo
Outcome Measures: Reduction in incidence of trastuzumab-induced cardiotoxicity after 52 weeks of treatment as measured by preservation of LVEF;   Comparison of the LVEF of each treatment group with the placebo arm;   Number of trastuzumab courses completed without interruption;   Quality-of-life changes as assessed by EORTC-QLQ-C30 questionnaire at baseline and at the end of treatment;   Long-term effects of study drugs as assessed at 18 and 24 months (or 6 and 12 months after completion of trastuzumab therapy)
3 Recruiting Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer
Conditions: Dyspnea;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer
Interventions: Drug: Lisinopril;   Drug: placebo
Outcome Measures: Incidence of grade 3 or higher hypotension, acute kidney injury, allergic reaction, or anaphylaxis, as measured using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0;   Incidence of adverse events as measured using the NCI CTCAE version 4.0;   Quality of life, assessed using lung cancer symptom scale (LCSS), Functional Assessment of Cancer Treatment Lung Cancer (FACT-L), and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer (EORTC-QLQ-LC13);   Incidence of acute respiratory distress (dyspnea), measured using the maximum score, at any time, of the shortness of breath question on the LCSS;   Patient-level symptoms as measured using the Symptom Experience Questionnaire (SEQ)
4 Not yet recruiting CAndesartan vs Lisinopril Effects on the BRain
Conditions: Hypertension;   Mild Cognitive Impairment
Interventions: Drug: Candesartan;   Drug: Lisinopril
Outcome Measures: Executive function (EXAMINER score);   Perfusion and Vasoreactivity (VR);   rs-fMRI
5 Recruiting Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies
Conditions: Duchenne Muscular Dystrophy;   Becker Muscular Dystrophy;   Limb Girdle Muscular Dystrophy
Intervention: Drug: Coenzyme Q10 and Lisinopril
Outcome Measure: myocardial performance index (MPI)
6 Unknown  Paramedic Initiated Lisinopril For Acute Stroke Treatment
Condition: Stroke
Interventions: Drug: Lisinopril;   Drug: Placebo
Outcome Measures: Number of participants enrolled per month;   Proportion fulfilling eligibility criteria;   Proportion attended by research trained paramedic;   Proportion enrolled by research trained paramedic;   Proportion approached but not enrolled;   Additional time spent on scene;   Paramedic compliance;   Hospital staff compliance;   Proportion completing study medication;   Clinical outcome measures;   Adverse events
7 Recruiting Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease
Condition: Type 2 Diabetes
Interventions: Drug: ACEI or ARB;   Drug: Lisinopril
Outcome Measures: Change in renal blood flow (RBF);   Change in Proteinuria
8 Recruiting Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study
Condition: Hypertension
Intervention: Drug: Lisinopril, Atenolol
Outcome Measure: One type of blood pressure medication will better treat individuals with certain genetic backgrounds.
9 Recruiting Non-invasive Haemodynamic Assessment in Hypertension
Condition: Arterial Hypertension
Interventions: Drug: Lisinopril;   Drug: Telmisartan;   Drug: Nebivolol;   Drug: Indapamide/hydrochlorothiazide;   Drug: Amlodipine
Outcome Measures: 24-h mean Systolic Blood Pressure (in ABPM);   24-h mean Diastolic Blood Pressure (in ABPM);   daytime mean Systolic Blood Pressure (in ABPM);   daytime mean Diastolic Blood Pressure (in ABPM);   night-time mean Systolic Blood Pressure (in ABPM);   night-time mean Diastolic Blood Pressure (in ABPM);   Systolic Blood Pressure (in OBPM);   Diastolic Blood Pressure (in OBPM);   change from baseline in Systolic Blood Pressure (in OBPM) at 3 months;   change from baseline in Diastolic Blood Pressure (in OBPM) at 3 months;   change from baseline in 24-h Systolic Blood Pressure (in ABPM) at 3 months;   change from baseline in 24-h Diastolic Blood Pressure (in ABPM) at 3 months;   change from baseline in daytime Systolic Blood Pressure (in ABPM) at 3 months;   change from baseline in daytime Diastolic Blood Pressure (in ABPM) at 3 months;   change from baseline in night-time Systolic Blood Pressure (in ABPM) at 3 months;   change from baseline in night-time Diastolic Blood Pressure (in ABPM) at 3 months
10 Recruiting The VALDIATE-D Study
Conditions: Type 2 Diabetes;   Obesity
Interventions: Drug: Calcitriol and Lisinopril;   Drug: Placebo
Outcome Measures: Circulating RAS activity after calcitriol/placebo therapy;   Renal-vascular tissue RAS activity after calcitriol/placebo therapy;   Renal-vascular RAS activity and urien protein after calcitriol/Lisinopril therapy;   Adiponectin levels;   Adipose-tissue RAS measures
11 Not yet recruiting Single Pill to Avert Cardiovascular Events
Condition: Cardiovascular Disease
Interventions: Drug: polipillV1;   Drug: polipillV2;   Drug: usual care
Outcome Measures: compliance with treatment;   changed in blood pressure;   changes in LDL-cholesterol levels;   the main reason for non compliance with treatment;   safety of poli pill measures by laboratorial tests;   combined outcome
12 Recruiting ACE Inhibitors to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Patients: A Pilot Study
Condition: HIV
Interventions: Drug: Lisinopril;   Drug: Placebo
Outcome Measures: Change in HIV RNA (copies/mil CD4);   Change in HIV DNA (copies/mil CD4)
13 Recruiting The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
Condition: Hyperparathyroidism
Interventions: Drug: captopril;   Drug: Lisinopril
Outcome Measures: Parathyroid hormone, before and after, ACE inhibitor administration;   Serum and urinary aldosterone measurements before and after ACE inhibitor use;   Serum calcium before and after ACE inhibitor administration
14 Recruiting Risk Factor Control Before Orthopedic Surgery
Conditions: Osteoarthritis;   Cardiovascular Disease
Interventions: Drug: Metoprolol;   Drug: Lisinopril;   Drug: Atorvastatin;   Behavioral: Lifestyle counseling
Outcome Measures: Composite of cardiovascular events;   Modified composite of cardiovascular events
15 Not yet recruiting Microvascular Disease Exercise Trial
Condition: Coronary Microvascular Disease
Interventions: Behavioral: Exercise Program;   Drug: Medical Therapy
Outcome Measures: Change in MPR on CMR imaging from baseline with intensive medical therapy + supervised exercise versus intensive medical therapy alone.;   Incremental change in MPR with exercise over intensive medical therapy alone in the exercise subgroup;   Identification of reduced MPR (<2.0 ml/g/min) and borderline reduced MPR
16 Not yet recruiting Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery
Condition: Hypertension
Interventions: Drug: Take ACE-I;   Drug: Hold ACE-I
Outcome Measures: Intraoperative Hypotension;   Acute Renal Failure;   Low blood pressure subgroup;   Older age subgroup;   Postoperative Hypertension
17 Recruiting Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Cardiovascular Risk Assessment
Conditions: Essential Hypertension;   Cardiovascular Disease;   Stroke;   Chronic Kidney Disease
Interventions: Drug: Any antihypertensive medication alone or in combination;   Device: Ambulatory blood pressure monitoring
Outcome Measures: To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular and renal risk assessment.;   To evaluate the influence of circadian time of treatment in BP control of hypertensive patients.;   To evaluate the prevalence of an altered (non-dipper) BP profile in patients with resistant hypertension as a function of the circadian time of treatment.;   To evaluate the influence of diabetes and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.;   To evaluate the influence of age and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.;   To evaluate, for all groups of interest, the prevalence and cardiovascular risk profile of white-coat hypertension.;   To evaluate, for all groups of interest, the prevalence and cardiovascular risk profile of masked hypertension.;   To evaluate, for all previous objectives, potential differences between men and women.;   To evaluate the impact of changes in ambulatory BP in cardiovascular, cerebrovascular and renal risk assessment.
18 Unknown  Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease
Conditions: Cardiovascular Disease;   Chronic Kidney Disease
Interventions: Drug: angiotensin converting enzyme inhibitor;   Drug: Lisinopril
Outcome Measure: There may be a statistical correlation between eGFR(estimated glomerular function) and PWV (pulse wave velocity) in patients with CKD, the addition of an ACE inhibitor will decrease PWV in all groups, but to a greater extent in patients wil CKD.
19 Recruiting Renal Denervation in Patients After Acute Coronary Syndrome
Conditions: Acute Coronary Syndrome;   Arterial Hypertension
Interventions: Procedure: Renal denervation;   Drug: Metoprolol;   Drug: Lisinopril
Outcome Measures: cardiovascular death;   myocardium infarction;   stroke;   repeat revascularization;   blood pressure changes;   CCS and NYHA;   heart rhythm disturbances;   intima-media index;   IVS thickness;   restenosis;   diastolic disfunction
20 Unknown  Is There a Benefit to Optimize Heart Failure (HF) Treatment in Aged Over 80 Year's Old Patients?
Condition: Heart Failure
Intervention: Drug: - Angiotensin conversing enzyme inhibitors: enalapril, captopril, Lisinopril, ramipril, trandolapril.
Outcome Measures: Change from baseline in quality of life;   Mortality;   Rehospitalisation;   Cardiovascular events;   Cardiac fibrosis;   Quality of life